55 results
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
14 Feb 24
Third party tender offer statement (amended)
10:35am
Subsidiaries of intellectual property rights but excluding (i) any costs related to a breach of this Agreement, including costs incurred in litigation
SC TO-T/A
EX-99
THRX
Theseus Pharmaceuticals Inc
30 Jan 24
Third party tender offer statement (amended)
8:23am
Agreement; and the risk that stockholder litigation in connection with the Offer or the merger may result in significant costs of defense
SC TO-T/A
EX-99
THRX
Theseus Pharmaceuticals Inc
30 Jan 24
Third party tender offer statement (amended)
8:23am
will not sustain any challenge by the IRS in the event of litigation.
Holders are urged to consult their tax advisors to determine the tax consequences … , as of particular dates, concerning Theseus’ business, principal physical properties, capital structure, material pending litigation, operating results, financial
SC 14D9
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Tender offer solicitation
9:47am
litigation that Theseus is aware of challenging the Offer, the Merger or the other Transactions.
Regulatory Approvals
Parent and Theseus are not currently … of its common stock; significant costs associated with the proposed Transactions; the risk that any stockholder litigation in connection
SC TO-T
EX-99
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Third party tender offer statement
8:51am
that the IRS will not take a position contrary to the discussion below, or that a court will not sustain any challenge by the IRS in the event of litigation … , as of particular dates, concerning Theseus’
business, principal physical properties, capital structure, material pending litigation, operating results, financial
SC TO-T
EX-99
vqchtzaozp sw
10 Jan 24
Third party tender offer statement
8:51am
SC14D9C
EX-99.1
skgucsd9n0m nhs8mdn
22 Dec 23
Written communication relating to third party tender offer
6:52am
SC14D9C
zvmhhm5j
22 Dec 23
Written communication relating to third party tender offer
6:52am
8-K
EX-2.1
pvg6g414zdv8ru591
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-99.1
kn6to6r
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
7crr9ybrhk40n
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-10.1
mlpgspuz4g vjv68gp8h
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.3
if52 v9dcjq
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
dcye1
27 Nov 23
Other Events
6:37am
8-K
EX-10.2
fj6qa1ot 28p
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
8-K
EX-99.1
biy8rfj
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
8-K
10v7h0q523259
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm